| CAS NO: | 77337-73-6 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| 1g | 电议 |
| 2g | 电议 |
| Molecular Weight (MW) | 400.47 |
|---|---|
| Formula | C10H20CaN2O8S2 |
| CAS No. | 77337-73-6 (calcium salt); 77337-76-9 (free acid) |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: N/A |
| Water: ≥ 100 mg/mL (499.40 mM) | |
| Ethanol: <1 mg/mL | |
| Solubility (In vivo) | N/A |
| SMILES Code | O=S(CCCNC(C)=O)([O-])=O.O=S(CCCNC(C)=O)([O-])=O.[Ca+2] |
| Synonyms | Campral EC; Calcium N-acetylhomotaurinate; Alcomed; Aotal; Campral; Sobriol; Acamprosate calcium |
| Other info | Chemical Name: Calcium 3-(acetylamino)propane-1-sulfonate InChi Key: BUVGWDNTAWHSKI-UHFFFAOYSA-L InChi Code: InChI=1S/2C5H11NO4S.Ca/c2*1-5(7)6-3-2-4-11(8,9)10;/h2*2-4H2,1H3,(H,6,7)(H,8,9,10);/q;;+2/p-2 |
| In Vitro | In vitro activity: Acamprosate has low bioavailability, but also has an excellent tolerability and safety profile. In comparison with naltrexone and disulfiram, which are the other FDA-approved treatments for alcohol dependence, acamprosate is unique in that it is not metabolized by the liver and is also not impacted by alcohol use, so can be administered to patients with hepatitis or liver disease (a common comorbid condition among individuals with alcohol dependence) and to patients who continue drinking alcohol. |
|---|---|
| In Vivo | Acamprosate calcium(Campral EC) is a GABA receptor agonist and modulator of glutamatergic systems; reduces alcohol consumption in animal models of alcohol addiction. |
| Animal model | N/A |
| Formulation & Dosage | N/A |
| References | Alcohol Clin Exp Res. 2012 Jun;36(6):967-9.; Ther Clin Risk Manag. 2012;8:45-53. |
m.cnreagent.com